
<table style="text-align:center"><caption><strong>US Market Authorization Counts for Orphan Drugs with Over 5 Market Authorizations</strong></caption>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr><tr><td>Generic Name</td><td>Market Authorizations</td></tr>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr><tr><td>nivolumab</td><td>16</td></tr>
<tr><td>pembrolizumab</td><td>16</td></tr>
<tr><td>bevacizumab</td><td>11</td></tr>
<tr><td>ibrutinib</td><td>11</td></tr>
<tr><td>ivacaftor</td><td>11</td></tr>
<tr><td>olaparib</td><td>11</td></tr>
<tr><td>lenalidomide</td><td>9</td></tr>
<tr><td>lisocabtagene maraleucel</td><td>9</td></tr>
<tr><td>adalimumab</td><td>7</td></tr>
<tr><td>axicabtagene ciloleucel</td><td>7</td></tr>
<tr><td>brentuximab vedotin</td><td>7</td></tr>
<tr><td>crizotinib</td><td>7</td></tr>
<tr><td>daratumumab</td><td>7</td></tr>
<tr><td>ravulizumab-cwvz</td><td>7</td></tr>
<tr><td>zanubrutinib</td><td>7</td></tr>
<tr><td>canakinumab</td><td>6</td></tr>
<tr><td>isavuconazonium sulfate</td><td>6</td></tr>
<tr><td>rituximab</td><td>6</td></tr>
<tr><td>selpercatinib</td><td>6</td></tr>
<tr><td colspan="2" style="border-bottom: 1px solid black"></td></tr></table>
